Potential cardiovascular benefits of therapies for COPD
In the present study, patients with cardiovascular risk factors or disease at baseline had two to three times the MACE rate as patients without these at baseline. In both subgroups of patients, roflumilast conveyed a reduction in cardiovascular events, although […]